Alopecia areata, also known as spot baldness, is a condition in which hair is lost from some or all areas of the body. Often it results in a few bald spots on the scalp, each about the size of a coin. Psychological stress may result. People are generally otherwise healthy. In a few, all the hair on the scalp or all body hair is lost and loss can be permanent.
Alopecia areata is believed to be an autoimmune disease resulting from a breach in the immune privilege of the hair follicles. Risk factors include a family history of the condition. Among identical twins if one is affected the other has about a 50% chance of also being affected. The underlying mechanism involves failure by the body to recognize its own cells with subsequent immune mediated destruction of the hair follicle.
Many Alopecia patients do not visit hospitals and try to self-treatment with hair care products.
It has been found that Alopecia patients in Korea are more likely to self-treatment through hair care products before visiting hospitals compared to other countries. (Inha University)
The Alopecia market is estimated to grow every year
In particular, the size of the hair care market is growing mainly due to hair loss shampoo and the blue ocean of hair care market
The size of the hair care market is estimated to be around 700 billion won, with half of them expected to surpass the Alopecia management market (Hana Financial Investment Research Center).
As the mechanism of Alopecia moves from depilation anagen to depilation catagen, the death of cells by ROS occurs.
Cell death by ROS is caused by Nox family leading the production of free radicals in the hair follicle cells, so we consider Nox as a new target for Alopecia prevention.
This technology is the raw material derived from the Ministry of Science, ICP and Future Planning's 'Redox mix functional research- Cell Signal Transfer by Redox' project.
|Classification||PIPELINE||Candidate material||Preclinical||Clinical||New Drug approval||Item permit|
|Alopecia / Depilation
Completed development of candidate materials, pre-clinical development phase
The medical institution plans to utilize hair loss treatment-related functional cosmetics and medicines
A composition for preventing alopecia and promoting depilation including acetoxychavicol acetate as active ingredient
(registration number : 1020170012315, 2017.01)